CD8A and neoplasm: IL-21 fused to anti-PD-1 antibody stimulated generation of Tscm with enhanced cell proliferation and tumor-specific CD8+ T cells, outperforming anti-PD-1 antibody and IL-21 infused as separate treatments (147).